ProCE Banner Activity

Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing: Experts Answer Clinician Questions

Podcast Episodes
Listen to George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer audience questions from a series of live CCO Webinars focused on when and how to test for NTRK fusions in solid tumors and best practices in using TRK inhibitors.

Released: August 14, 2020

Expiration: August 13, 2021

Share

Faculty

George D. Demetri

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander E Drilon

Alexander E Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Pashtoon M. Kasi

Pashtoon M. Kasi, MD, MS

Director 
Colon Cancer Research 
Weill Cornell Medicine
Director 
Liquid Biopsy Research 
Englander Institute of Precision Medicine 
New York, New Yotk

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Genentech TEXT Only

Program Director Disclosure

Program Director

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received consulting fees from AbbVie, Adaptimmune, Bayer, Bessor, Blueprint, Caprion/HistoGeneX, Caris Life Sciences, Champions Biotechnology, Daiichi-Sankyo, EMD Serono, Epizyme, Erasca, G1 Therapeutics, GlaxoSmithKline, ICON, Ignyta, Janssen, Loxo Oncology, Merrimack, Mirati, MJ Hennessy/OncLive, Novartis, PharmaMar, Pfizer, Polaris, Relay Therapeutics, Roche/Genentech, Sanofi, Translate Bio, WCG/Arsenal Capital, and ZioPharm and royalties paid to his institution from Novartis.

Faculty Disclosure

Primary Author

Alexander E Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, BeiGene, BerGenBio, Blueprint, Exelixis, Helsinn, Hengrui, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, MORE Health, Pfizer, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; funds for research support from Foundation Medicine; and funds for research support paid to his institution from Exelixis, GlaxoSmithKline, Pfizer, PharmaMar, Taiho, and Teva.

Pashtoon M. Kasi, MD, MS

Director 
Colon Cancer Research 
Weill Cornell Medicine
Director 
Liquid Biopsy Research 
Englander Institute of Precision Medicine 
New York, New Yotk

Pashtoon Kasi, MD, has disclosed that he has received consulting fees from Foundation Medicine, Ipsen, Natera, and Taiho (paid to his institution) and funds for research support from Amgen, Array, AstraZeneca, BTG, Clovis, and RenovoRx.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstom has no relevant conflicts of interest to report.

Additional Information

Program Medium

This program has been made available online.